
5/13/2014 PERIPHERAL



## PERIPHERAL & CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE

June 6, 2001

## **Briefing Information**

Consideratin of NDA 21-196, Xyrem (sodium oxybate, Orphan Medial Inc.), proposed to reduce the incidence of cataplexy and to improve the symptom of daytime sleepiness for persons wit narcolepsy.

## **Orphan Medical Presentations**

Disclaimer

The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

**Briefing Information** pdf

**Xyrem Prescription and Distribution Process,** Video Script 2/2/01) <a href="https://html">html</a> <a href="pdf">pdf</a>

**Video** 

**FDA Briefing Information** 

Index pdf

Overview Memo pdf

Efficacy Review pdf

Safety Review pdf

Major Amendment Review pdf

Controlled Substance Overview pdf

